Seeking Alpha

Curis reaffirmed a Buy at Roth

  • "We believe market growth (for Erivedge) will continue in 2014, providing a revenue stream and increasing visibility for Curis (CRIS -4.2%)," says analyst Joe Pantginis. He notes Erivedge revenue has grown continuously since its 2012 launch, with Roche reporting $28M in Q4 sales. Curis, of course, receives royalty payments on those sales.
  • Adding to that, says Pantginis, is increased clarity on Curis' internal pipeline.
  • Earnings coverage last Thursday
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs